17,261 trials
Acute Lymphoid Leukemia · Acute Myeloid Leukemia · Anemia, Refractory, With Excess of Blasts
Primary: Objective Response Rate (ORR) by Investigator — 12; 14 percentage of participants
Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of All Study Therapy (SVR12) — 58.3; 90.0 Percentage of participants
Chronic Hepatitis C (CHC)
Primary: Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks After the End of Treatment (SVR12) — 54.2; 84.0; 88.5 percentage of participants
Hepatitis C Virus
Primary: Percentage of Participants Achieving Sustained Virologic Response (SVR) at 12 Weeks After the End of All Study Therapy (SVR12) — 97.1 Percentage of participants
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 95.5; 87.5 percentage of participants
Neovascular Age-Related Macular Degeneration
Primary: Evidence of Anterior Chamber Inflammation — 1; 10; 0; 1 participants
Cancer
Primary: Number of Participants With Indicated Non-progressive Disease as Assessed by Investigator Per Response Evaluation Criteria In Solid Tumor Version 1.1 (RECIST 1.1) at…
Aplastic Anemia
Primary: Participants no Longer Meeting Criteria for Severe Aplastic Anemia. — 18; 17; 9; 9 participants
Medulloblastoma · Rhabdomyosarcoma · Neuroblastoma
Primary: Number of Participants With Dose-limiting Toxicities (DLT) in Phase I — 0; 1; 0; 0 participants
Aplastic Anemia · Neutropenia · Pancytopenia
Primary: Response Rate at 6 Months — 1; 0; 0 participants
Advanced Cancers
Primary: Number of Participants Completing Study Intervention — 7; 10; 3; 5 Participants
Urothelial Cancer
Primary: Objective Response Rate (ORR, CR+PR) in Patients With Advanced/Metastatic UC Treated With the Combination of Gemcitabine, Cisplatin, and Sunitinib. — 48.5 Percentage of…
Hemophilia A · Von Willebrand Disease
Primary: Biologic Effects by Coagulation Tests — 34.75; 143.4 percentage of normal
Non-small-cell Lung Cancer
Primary: Response Assessment by Study Stratum - Per Investigator Assessment — 0; 6; 3; 7 Participants
Hepatitis C, Chronic
Primary: Percentage of Participants Achieving Complete Early Viral Response (cEVR) — 94.4; 80.3; 85.3; 87.5 percentage of participants